Brainvectis was laureate of the 2017 National Research Agency call for proposal

By August 1, 2017Non class

 

Along with its academic partners, BrainVectis was selected during the call for proposal 2017 of the National Research Agency, for the development of its gene therapy program in Huntington’s disease.

The consortium will receive a grant of 534K euros to finance the development of the program for 2 years: development of BV-CYP01 biomanufacturing, injection studies in primate, and complete characterization of cholesterol metabolism in a cohort of Huntington patients.

Our partners are the CEA, the Institute of the Brain and the Marrow (ICM) and Nathalie Cartier’s laboratory (Inserm).

ANR mission is to finance French research projects. It is based on a competitive selection process that meets international standards. This year, the selection rate was 12.6%.